Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast Cancer

Release Date: October 31, 2017
Expiration Date: October 31, 2018
Media: Internet - based


Activity Overview

The expanding arsenal of targeted therapies available for the treatment of patients with metastatic breast cancer is allowing us to continually hone treatment and personalize care. While novel therapies and combinations— including those utilizing oral, CDK4/6 inhibitors—undeniably benefit patients with breast cancer, they also add markedly to the complexity of care. It is key for practitioners to be able to assimilate the latest clinical evidence, thus optimizing efficacy and mitigating the chance for toxicities for these most difficult-to-treat patients. This activity provides recent clinical data and expert perspectives regarding CDK4/6 inhibitors and their use in the management of patients with estrogen-receptor positive, metastatic breast cancer, which can help the multidisciplinary team to further establish state-of-the-art treatment practices.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

CME/CE Activity Table of Contents

  • Understanding of the Role of CDK4/6 Inhibition in the Treatment of Metastatic Breast Cancer
  • CDK4/6 Inhibition: Clinical Applications and Supporting Evidence
  • Optimizing the Safety of CDK4/6 Inhibitor Application
  • Individualizing CDK4/6 Inhibitor Therapy and Future Applications

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This activity is directed toward medical, surgical and radiation oncologists who treat or manage patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Assess pharmacodynamics properties of cyclin-dependent kinase (CDK) 4/6 inhibition and how that is currently applied to the management of metastatic breast cancer
  • Discuss pivotal trial results concerning the use of CDK4/6 inhibitors in the treatment of metastatic breast cancer
  • Translate evolving evidence to apply CDK4/6 inhibitor approaches to the care of patients with metastatic breast cancer
  • Identify strategies that can be integrated by multidisciplinary teams in institutions for the mitigation and management of predictable adverse events associated with emerging CDK4/6 inhibitory therapies in the management of metastatic breast cancer

Faculty, Staff, and Planners' Disclosures


Francisco J. Esteva, MD, PhD
Professor of Medicine (Oncology)
Director, Breast Medical Oncology Program
Associate Professor of Clinical Investigation
Laura and Isaac Perlmutter Cancer Center
New York University Langone Medical Center
New York, NY

Disclosure: Consultant: Novartis, Genentech; Grant/Research Support: Novartis, Merrimack, Kadmon, Pfizer.

Sara Hurvitz, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Director, Breast Cancer Clinical Research Program
Outpatient Hematology/Oncology
University of California, Los Angeles
Santa Monica, CA

Disclosure: Grant/Research Support: Amgen, Bayer, Boehringer Ingelheim, Genentech, GSK, Pfizer, Roche, Biomarin, Merrimack, OBI Pharm, PUMA, Dignitana, Medivation, Lilly, Novartis, OBI.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Filter By